NCT01349790View on ClinicalTrials.gov

Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia

PHASE3CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions

Primary Thrombocytopenia

Interventions

DRUG

NewGam

NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.

Trial Locations (1)

Unknown

Abdulgabar Salama, Berlin

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Octapharma

INDUSTRY